Street Calls of the Week
On September 29, 2025, Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), sold 14,023 shares of common stock. The sales were executed at prices ranging from $416.596 to $430.7482, resulting in a total transaction value of $9.49 million. The transaction comes as the $19.84 billion market cap company trades near its 52-week high of $442.01, having delivered an impressive 36.6% return over the past six months. According to InvestingPro, the company maintains an Excellent Financial Health Score of 3.86.
According to a Form 4 filing with the Securities and Exchange Commission, the transactions were executed under a pre-arranged Rule 10b5-1 trading plan.
On the same day, Benkowitz also exercised stock options to acquire 22,500 shares of United Therapeutics common stock. These options were exercised at prices of $135.42 and $146.03, for a total value of $3.13 million.
The shares sold were held by trusts for which Benkowitz or his family members are beneficiaries. Following these transactions, Benkowitz directly holds 2,648 shares of United Therapeutics Corp .
In other recent news, United Therapeutics has been the focus of multiple analyst evaluations and legal proceedings. UBS has maintained its Buy rating and increased its price target to $580, citing the outlook for Tyvaso, despite slightly lowering its revenue forecast for the drug in the third quarter of 2025 to $496 million. Additionally, UBS adjusted its full-year 2025 revenue projection for Tyvaso to $1.93 billion. Meanwhile, H.C. Wainwright has also reiterated a Buy rating with a $500 price target as the company navigates ongoing patent litigation with Liquidia. The litigation involves United Therapeutics’ PH-ILD patent, with a court decision expected in late 2025. TD Cowen has expressed continued confidence in the company, maintaining a Buy rating and $500 price target following the presentation of promising Phase III Tyvaso data in idiopathic pulmonary fibrosis patients. RBC Capital has initiated coverage on United Therapeutics with an Outperform rating and a $569 price target, highlighting the company’s leadership in rare lung diseases and its promising pipeline opportunities. These developments reflect a consistent positive outlook from analysts despite the ongoing legal challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.